Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
03692 HANSOH PHARMA
RTNominal down18.000 -0.320 (-1.747%)
Others

22/06/2020 12:12

Hansoh Pharma (03692) gets drug registration approval

[ET Net News Agency, 22 June 2020] Hansoh Pharmaceutical Group Company Limited (03692)
said "Olanzapine Orally Disintegrating Tablets", developed by Jiangsu Hansoh
Pharmaceutical Group Co., Ltd., a subsidiary of the Company, has been granted drug
registration approval by the National Medical Products Administration of the People's
Republic of China.
The product is an atypical antipsychotic agent indicated for (1) treatment of
schizophrenia; (2) maintenance treatment for patients with effective initial treatment of
olanzapine, which can effectively maintain improvement in clinical symptoms; (3) treatment
of moderate-to-severe manic episode; and (4) recurrence prevention of bipolar disorder for
manic episodes with effective initial treatment of olanzapine. (RC)

Back to Others

Remark: Real time quote last updated: 08/05/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.